Mallinckrodt appoints Dr. Marek Honczarenko as EVP and Chief Scientific Officer

Keenova Therapeutics plc

Dr. Honczarenko joins effective Sept 29, 2025, from Sun Pharma where he was SVP and Head of Development.
He succeeds Dr. Peter Richardson, whose departure was previously announced for other interests.
CEO Siggi Olafsson noted timing aligns with July 2025 Endo merger and planned generics spin-off.
Honczarenko brings 25+ years experience at GSK, AbbVie, BMS, Pfizer, and Biogen in specialty therapeutics.
He has served on FDA Arthritis Advisory Committee as Industry Representative since 2019.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.